Moreover, the 36-month beta value for CADL is -0.36. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CADL is 15.66M and currently, short sellers hold a 1.03% of that float. On April 24, 2024, CADL’s average trading volume was 5.28M shares.
CADL) stock’s latest price update
The stock price of Candel Therapeutics Inc (NASDAQ: CADL) has surged by 3.39 when compared to previous closing price of 5.91, but the company has seen a 12.32% gain in its stock price over the last five trading sessions. Seeking Alpha reported 2024-04-15 that Candel Therapeutics, Inc. released positive interim results from the phase 2 study using CAN-2409 for treatment of patients with pancreatic ductal adenocarcinoma; Patients that took the drug with SOC achieved mOS of 28.8 months. Orphan Drug Designation is given by FDA for CAN-2409 for the treatment of patients with borderline respectable pancreatic ductal adenocarcinoma. Results from phase 2 study using CAN-2409 for the treatment of patients with non-small cell lung cancer, expected Q2 of 2024.
CADL’s Market Performance
Candel Therapeutics Inc (CADL) has seen a 12.32% rise in stock performance for the week, with a 301.98% gain in the past month and a 381.11% surge in the past quarter. The volatility ratio for the week is 11.48%, and the volatility levels for the past 30 days are at 31.12% for CADL. The simple moving average for the last 20 days is 32.02% for CADL stock, with a simple moving average of 297.35% for the last 200 days.
Analysts’ Opinion of CADL
Many brokerage firms have already submitted their reports for CADL stocks, with H.C. Wainwright repeating the rating for CADL by listing it as a “Buy.” The predicted price for CADL in the upcoming period, according to H.C. Wainwright is $11 based on the research report published on December 02, 2022 of the previous year 2022.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see CADL reach a price target of $18. The rating they have provided for CADL stocks is “Outperform” according to the report published on November 19th, 2021.
UBS gave a rating of “Buy” to CADL, setting the target price at $9 in the report published on August 23rd of the previous year.
CADL Trading at 115.93% from the 50-Day Moving Average
After a stumble in the market that brought CADL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.40% of loss for the given period.
Volatility was left at 31.12%, however, over the last 30 days, the volatility rate increased by 11.48%, as shares surge +309.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +338.85% upper at present.
During the last 5 trading sessions, CADL rose by +12.13%, which changed the moving average for the period of 200-days by +408.33% in comparison to the 20-day moving average, which settled at $4.86. In addition, Candel Therapeutics Inc saw 315.65% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CADL
The total capital return value is set at -1.4. Equity return is now at value -125.50, with -63.12 for asset returns.
Based on Candel Therapeutics Inc (CADL), the company’s capital structure generated 0.63 points at debt to capital in total, while cash flow to debt ratio is standing at -1.57. The debt to equity ratio resting at 1.71. The interest coverage ratio of the stock is -51.19.
Currently, EBITDA for the company is -37.19 million with net debt to EBITDA at 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.59.
Conclusion
To wrap up, the performance of Candel Therapeutics Inc (CADL) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
